Literature DB >> 10612800

Comparison between genotype and phenotype identifies a high-risk population carrying BRCA1 mutations.

L Cortesi1, D Turchetti, C Bertoni, R Bellei, L Mangone, M Vinceti, M Federico, V Silingardi, S Ferrari.   

Abstract

Hereditary breast carcinomas constitute about 10% of all malignant mammary tumors, but the selection criteria to identify a high-risk population carrying BRCA1 mutations are not yet well-defined. We have collected 51 pedigrees of familial breast cancer, 16 pedigrees of familial breast and ovarian cancer, and 30 cases of early-onset breast cancer (<35 years of age) without any family history of breast cancer. The index cases of the 97 selected families were further subdivided into three groups based on histopathological parameters: group A (n = 19) was characterized by tumor grade III, negative estrogen and progesterone receptors, and high proliferative rate; group B (n = 20) was characterized by grade I-II tumors, positive hormonal receptors, and low proliferative rate; and group C (n = 58) was not homogeneous for the histopathological criteria. The aim of our study was to evaluate, in patients with a family history of breast cancer or with early diagnosis of breast cancer, the incidence of BRCA1 mutation on the basis of tumor phenotype. We found the highest rate of BRCA1 mutations in group A (53%), and low frequencies in groups B (5%) and C (0%). Our data strongly indicate that an aggressive tumor phenotype in patients with a positive family history or early diagnosis identifies a population with high probability of carrying BRCA1 mutations. Genes Chromosomes Cancer 27:130-135, 2000. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10612800

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  8 in total

1.  Determining the identifiability of DNA database entries.

Authors:  B Malin; L Sweeney
Journal:  Proc AMIA Symp       Date:  2000

2.  Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

Authors:  Nasim Mavaddat; Daniel Barrowdale; Irene L Andrulis; Susan M Domchek; Diana Eccles; Heli Nevanlinna; Susan J Ramus; Amanda Spurdle; Mark Robson; Mark Sherman; Anna Marie Mulligan; Fergus J Couch; Christoph Engel; Lesley McGuffog; Sue Healey; Olga M Sinilnikova; Melissa C Southey; Mary Beth Terry; David Goldgar; Frances O'Malley; Esther M John; Ramunas Janavicius; Laima Tihomirova; Thomas V O Hansen; Finn C Nielsen; Ana Osorio; Alexandra Stavropoulou; Javier Benítez; Siranoush Manoukian; Bernard Peissel; Monica Barile; Sara Volorio; Barbara Pasini; Riccardo Dolcetti; Anna Laura Putignano; Laura Ottini; Paolo Radice; Ute Hamann; Muhammad U Rashid; Frans B Hogervorst; Mieke Kriege; Rob B van der Luijt; Susan Peock; Debra Frost; D Gareth Evans; Carole Brewer; Lisa Walker; Mark T Rogers; Lucy E Side; Catherine Houghton; JoEllen Weaver; Andrew K Godwin; Rita K Schmutzler; Barbara Wappenschmidt; Alfons Meindl; Karin Kast; Norbert Arnold; Dieter Niederacher; Christian Sutter; Helmut Deissler; Doroteha Gadzicki; Sabine Preisler-Adams; Raymonda Varon-Mateeva; Ines Schönbuchner; Heidrun Gevensleben; Dominique Stoppa-Lyonnet; Muriel Belotti; Laure Barjhoux; Claudine Isaacs; Beth N Peshkin; Trinidad Caldes; Miguel de la Hoya; Carmen Cañadas; Tuomas Heikkinen; Päivi Heikkilä; Kristiina Aittomäki; Ignacio Blanco; Conxi Lazaro; Joan Brunet; Bjarni A Agnarsson; Adalgeir Arason; Rosa B Barkardottir; Martine Dumont; Jacques Simard; Marco Montagna; Simona Agata; Emma D'Andrea; Max Yan; Stephen Fox; Timothy R Rebbeck; Wendy Rubinstein; Nadine Tung; Judy E Garber; Xianshu Wang; Zachary Fredericksen; Vernon S Pankratz; Noralane M Lindor; Csilla Szabo; Kenneth Offit; Rita Sakr; Mia M Gaudet; Christian F Singer; Muy-Kheng Tea; Christine Rappaport; Phuong L Mai; Mark H Greene; Anna Sokolenko; Evgeny Imyanitov; Amanda Ewart Toland; Leigha Senter; Kevin Sweet; Mads Thomassen; Anne-Marie Gerdes; Torben Kruse; Maria Caligo; Paolo Aretini; Johanna Rantala; Anna von Wachenfeld; Karin Henriksson; Linda Steele; Susan L Neuhausen; Robert Nussbaum; Mary Beattie; Kunle Odunsi; Lara Sucheston; Simon A Gayther; Kate Nathanson; Jenny Gross; Christine Walsh; Beth Karlan; Georgia Chenevix-Trench; Douglas F Easton; Antonis C Antoniou
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-12-05       Impact factor: 4.254

Review 3.  The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers.

Authors:  Ana Cristina Vargas; Leonard Da Silva; Sunil R Lakhani
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

Review 4.  Genetic susceptibility to breast cancer.

Authors:  Nasim Mavaddat; Antonis C Antoniou; Douglas F Easton; Montserrat Garcia-Closas
Journal:  Mol Oncol       Date:  2010-05-21       Impact factor: 6.603

Review 5.  Phenotype-genotype correlation in familial breast cancer.

Authors:  Ana Cristina Vargas; Jorge S Reis-Filho; Sunil R Lakhani
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-03-12       Impact factor: 2.673

6.  Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer.

Authors:  Laura Cortesi; Cristina Masini; Claudia Cirilli; Veronica Medici; Isabella Marchi; Giovanna Cavazzini; Giuseppe Pasini; Daniela Turchetti; Massimo Federico
Journal:  BMC Cancer       Date:  2010-03-10       Impact factor: 4.430

7.  Incorporating tumour pathology information into breast cancer risk prediction algorithms.

Authors:  Nasim Mavaddat; Timothy R Rebbeck; Sunil R Lakhani; Douglas F Easton; Antonis C Antoniou
Journal:  Breast Cancer Res       Date:  2010-05-18       Impact factor: 6.466

8.  Genetic and epigenetic characterization of the BRCA1 gene in Brazilian women at-risk for hereditary breast cancer.

Authors:  Paula Silva Felicio; Matias Eliseo Melendez; Lidia Maria Rebolho Batista Arantes; Ligia Maria Kerr; Dirce Maria Carraro; Rebeca Silveira Grasel; Natalia Campacci; Cristovam Scapulatempo-Neto; Gabriela Carvalho Fernandes; Ana Carolina de Carvalho; Edenir Inêz Palmero
Journal:  Oncotarget       Date:  2017-01-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.